Analysis of the status of breast cancer specific gene 1 in triple negative breast cancer cancer patients and the efficacy and prognosis of immunotherapy
Objective To investigate the relationship between the status of BCSG1 and the efficacy and prognosis of immunotherapy in triple negative breast cancer(TNBC).Methods 150 patients with TNBC who received immunotherapy in the two hospitals from September 2016 to January 2022 were selected as research objects to detect the expression of BCSG1 in cancer tissues.According to the expression level of BCSG1,the patients were divided into high expression group(n=78)and low expression group(n=72)to explore the relationship between the expression level of BCSG1 and pathological fea-tures and the efficacy of immunotherapy.According to the prognosis,patients were divided into poor prognosis group(n=53)and good prognosis group(n=97),to explore the risk factors of poor prognosis after treatment,and build a prediction model.The survival rate of patients with different levels of BCSG1 expression was analyzed by using Kaplan-Meier survival curve.Results The expression level of BCSG1 was closely related to tumor diameter,TNM stage,tumor differentiation and lymph node metastasis(P＜0.05).The effective rate of BCSG1 low expression group was 79.17％,and that of BCSG1 high expression group was 53.85％.The high expression of BCSG1 was negatively correlated with the efficacy of immunotherapy(P＜0.05).Compared with the patients with good prognosis,the patients with poor prognosis were older,the tumor diameter was larger,the expression level of BCSG1 was higher,menopause,vascular tumor thrombus,lymph node metastasis,distant metastasis occurred more,TNM stage was mainly stage Ⅲ-Ⅳ,and the degree of tumor differentiation was mainly poor(P＜0.05).Tumor size≥5 cm,TNM stage Ⅲ-Ⅳ,low differentiation of tumor,lymph node metastasis,and high expression of BCSG1 were independent risk factors for poor prognosis of patients with TNBC after immunotherapy(P＜0.05).Kaplan-Meier survival curve showed that the survival rate of patients with high expression of BCSG1 was lower than that of patients with low ex-pression of BCSG1(P＜0.05).Conclusion The expression level of BCSG1 is high in TNBC patients with large tumor diameter,TNM stage Ⅲ-Ⅳ,low tumor differentiation and lymph node metastasis.The high expression of BCSG1 is an independent risk factor for poor prognosis of TNBC patients after immunotherapy,which can be used as an effective predictor of immuno-therapy efficacy and prognosis.
triple negative breast cancerBCSG1immunotherapycurative effectprognosis
NETL
NSTL
万方数据
